



December 18, 2025

British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission

Re: Conavi Medical Corp.

We refer to the short form prospectus of Conavi Medical Corp. ("Conavi") dated December 18, 2025 relating to the sale and issue of a minimum of \$15,000,000 and a maximum of \$20,000,000 of common shares or pre-funded warrants of Conavi (the "Prospectus").

We consent to being named and to the use, through incorporation by reference in the above-mentioned Prospectus, of our reports dated May 31, 2023 to the shareholders of Titan Medical Inc. ("Titan") and March 23, 2022 to the shareholders and board of directors of Titan on the following consolidated financial statements:

- o consolidated statements of financial position of Titan as at December 31, 2022 and 2021;
- o consolidated statements of net loss and comprehensive loss, cash flows and shareholders' equity(deficit) of Titan for the years ended December 31, 2022 and 2021, and notes to the consolidated financial statements including a summary of significant accounting policies.

We report that we have read the Prospectus and all information specifically incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the consolidated financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the Prospectus as these terms are described in the CPA Canada Handbook - Assurance.

Yours truly,

BDO Canada LLP

Chartered Professional Accountants, Licensed Public Accountants